Cytokinetics Presents New Data in Patients With
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and...
Source: globenewswire.com
📰 Dosing With News
Dosing With News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dosing With. Real-time updates on events, politics, business and more.
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical... | May 20, 2023
Source: marketscreener.com
Cytokinetics Presents Positive Results From Cohort 4 of
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive...
Source: globenewswire.com
Cytokinetics Presents New Data From REDWOOD-HCM OLE in
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows...
Source: globenewswire.com
Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late
New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten ...
Cytokinetics Incorporated Nasdaq National Harbor Society Scientific Sessions Randomized Evaluation Dosing With Obstructive Outflow Disease
Source: globenewswire.com
Cytokinetics Announces Upcoming Presentations at the 2022
Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLE...
Source: globenewswire.com
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics SOUTH SAN FRANCISCO, Calif., June 13, 2022 ... | June 13, 2022
Source: marketscreener.com
Cytokinetics Announces Additional Results From REDWOOD-HCM
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a...
United States San Francisco Theodore Abraham Diane Weiser University Of California Department Of Cardiology
Source: globenewswire.com
Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
03.06.2022 - SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive ... Seite 1
United States San Francisco Theodore Abraham Cytokinetics Incorporated Nasdaq University Of California Department Of Cardiology
Source: wallstreet-online.de
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
23.05.2022 - Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Analyses from GALACTIC-HF Show Patients with Low Blood Pressure Have ... Seite 1
Fadyi Malik Cytokinetics Incorporated Nasdaq International Congress European Society Of Cardiology Research Development Randomized Evaluation
Source: wallstreet-online.de